4
Changes in Ownership
CYTOKINETICS INC Filed Acc 0001127602-24-019272
EVP Research & Development sold 7,300 shares at an average $53.72 ($392,143)
- EVP Research & Development acquired 5,300 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham EVP Research & Development | 2024-06-25 | Sale 10b5-1 | −2,000 | $53.74 | $107,480 | 133,004 | D: show line 1 in the form |
| Malik Fady Ibraham EVP Research & Development | 2024-06-25 | Option exercise 10b5-1 | +5,300 | $7.96 | $42,188 | 138,304 | D: show line 2 in the form |
| Malik Fady Ibraham EVP Research & Development | 2024-06-25 | Sale 10b5-1 | −5,300 | $53.71 | $284,663 | 133,004 | D: show line 3 in the form |
| Open-market sales · 7,300 sh · avg $53.72 · $392,143 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham EVP Research & Development | 2024-06-25 | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 63,600 | D: show line 4 in the form |
Loading xslF345X05/form4.xml…